Peripheral artery disease: who works on it

One card per institution. Pick a target to see only the groups that work on it.

• All targets
• GLP-1 0
• SGLT2 0
• PCSK9 1
• AKT 0
• APOE 0
• PPAR 0
• ABL1 0
• CCR5 0
• ERK 0
• HIF-1 0
• IL-17 1
• NLRP3 0
• PTEN 0
• TNF 0
• TP53 0
• TREM2 0
• VEGF 0

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-ERC

  From niche to function: how endothelial cell interactions orchestrate muscle function in health and disease (InterECt)

  Eidgenoessische Technische Hochschule Zuerich· Zuerich, Switzerland· EU contribution €2,498,888· until Apr 2032

• European Commission (Horizon Europe) · HORIZON-ERC

  Single cEll guided polygeniC Risk prEdicTion of ASCVD (SECRET)

  Ita-Suomen Yliopisto· Kuopio, Finland· EU contribution €2,000,000· until Jun 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-EIC

  MultiomIcs based Risk stratification of Atherosclerotic CardiovascuLar disEase (MIRACLE)

  Ita-Suomen Yliopisto· Kuopio, Finland· EU contribution €4,599,866· until Sept 2027· 6 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  PERSONALIZED REHABILITATION VIA NOVEL AI PATIENT STRATIFICATION STRATEGIES (PREPARE)

  Aristotelio Panepistimio Thessalonikis· Thessaloniki, Greece· EU contribution €5,774,113· until May 2027· 9 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  DEVELOPING TRUSTWORTHY ARTIFICIAL INTELLIGENCE (AI)-DRIVEN TOOLS TO PREDICT VASCULAR DISEASE RISK AND PROGRESSION (VASCUL-AID)

  Stichting Amsterdam Umc· Amsterdam, Netherlands· EU contribution €5,969,125· until Apr 2029· 10 countries

5 of 5 running projects, newest first. Listed amounts together: €20.8m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 1
• Mendelian Randomization Analysis 18
• CRISPR-Cas Systems 1
• Gene Expression Profiling 5
• Proteomics 9
• Metabolomics 6
• Flow Cytometry 1
• Positron-Emission Tomography 3
• Magnetic Resonance Imaging 9
• Machine Learning 18
• Deep Learning 5
• Cohort Studies 53
• Genome-Wide Association Study 22

• Untargeted Plasma Metabolomics Reveals Molecular Subtypes Associated with Reintervention Risk in Peripheral Artery Disease after Revascularization.

  J Proteome Res, Nov 2026

• Residual lipid-related proteomic and metabolomic signatures associated with major adverse cardiovascular events after revascularization in peripheral artery disease.

  BMC Cardiovasc Disord, Sept 2026

• Metabolites Associated With Long-Term Risk of Peripheral Artery Disease: The ARIC Study.

  Arterioscler Thromb Vasc Biol, Aug 2026

• Impaired acute metabolic responses to submaximal exercise in peripheral artery disease (PAD).

  Vasc Med, Aug 2026

• Mitochondrial Omics in Macrophage Foam Cell Formation and Atherosclerosis.

  Proteomics, Aug 2026

• Resveratrol Promotes Angiogenesis in a FoxO1-Dependent Manner in Hind Limb Ischemia in Mice.

  Molecules, Dec 2021

See which targets of this disease your abstract mentions, and go to the people working on them.